Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Hayashi, Satoshi ^a   Kumai, Takumi ^a   Matsuda, Yoshiya ^a   Aoki, Naoko ^a   Sato, Keisuke ^a   Kimura, Shoji ^a   Kitada, Masahiro ^a   Tateno, Masatoshi ^a   Celis, Esteban ^b   Kobayashi, Hiroya ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; EPITOPE; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR15 ANTIGEN; HLA DR53 ANTIGEN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; GRANZYME; OXIDOREDUCTASE; PEPTIDE; STEAP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

ADULT; AGED; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL LYSATE; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; LUNG CARCINOMA; MALE; NONHUMAN; PREDICTION; PROTEIN FUNCTION; PROTEIN TARGETING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ADENOCARCINOMA; ALLELE; ANIMAL; ANTIGEN PRESENTATION; BLOOD; CELL CLONE; CELL LINE; CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; EPITOPES; FEMALE; GRANZYMES; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OXIDOREDUCTASES; PEPTIDES; TRANSCRIPTION FACTORS;

EID: 80355145650     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-191     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Douillard JY, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, Veillard AS, Seymour L, Le Chevalier T, Spiro S, Stephens R, Pignon JP, . LACE Collaborative Group Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010, 5:220-228. 10.1097/JTO.0b013e3181c814e7, 20027124, LACE Collaborative Group.
3. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood 2006, 108:1388-1394. 10.1182/blood-2006-02-003681, 1785011, 16609065.
4. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. PNAS 1999, 96:14523-14528. 10.1073/pnas.96.25.14523, 24469, 10588738.
5. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L, Jenuwein T. Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 1997, 16:3219-3232. 10.1093/emboj/16.11.3219, 1169939, 9214638.
6. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629. 10.1038/nature01075, 12374981.
7. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. PNAS 2003, 100:11606-11611. 10.1073/pnas.1933744100, 208805, 14500907.
8. Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol 2011, 38:345-353.
9. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008, 14:6790-6796. 10.1158/1078-0432.CCR-08-1013, 2690708, 18980972.
10. Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, Raitano AB, Jia XC, Gudas JM, Kanner SB, Jakobovits A. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007, 67:5798-5805. 10.1158/0008-5472.CAN-06-3849, 17575147.
11. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010, 116:3015-3024. 10.1002/cncr.25128, 20564407.
12. Giuntoli RL, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002, 8:922-931.
13. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995, 146:57-79. 10.1111/j.1600-065X.1995.tb00684.x, 7493761.
14. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998, 160:3363-3373.
15. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989, 12:2237-2242.
16. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000, 60:5228-5236.
17. Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 2008, 20:221-227. 10.1016/j.coi.2008.04.011, 2538913, 18499419.
18. Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, Kakizaki H, Tateno M. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J Urol 2010, 183:2036-2044. 10.1016/j.juro.2009.12.094, 20303532.
19. Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 2007, 67:5498-5504. 10.1158/0008-5472.CAN-07-0304, 17545632.
20. Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006, 55:1515-1523. 10.1007/s00262-006-0165-3, 16622681.
21. Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocyte. Clin Cancer Res 2005, 11:4545-4552. 10.1158/1078-0432.CCR-04-2235, 1698136, 15958640.
22. Oflazoglu E, Elliott M, Takita H, Ferrone S, Henderson RA, Repasky EA. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. J Transl Med 2007, 5:29. 10.1186/1479-5876-5-29, 1933531, 17592641.
23. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372. 10.1016/j.lungcan.2007.04.002, 2063443, 17509725.
24. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005, 65:6435-6442. 10.1158/0008-5472.CAN-05-0133, 16024648.
25. Wroblewski JM, Bixby DL, Borowski C, Yannelli JR. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer 2001, 33:181-194. 10.1016/S0169-5002(01)00210-0, 11551413.
26. Yano T, Fukuyama Y, Yokoyama H, Kuninaka S, Asoh H, Katsuda Y, Ichinose Y. HLA class I and class II expression of pulmonary adenocarcinoma cells and the influence of interferon gamma. Lung Cancer 1998, 20:185-190. 10.1016/S0169-5002(98)00010-5, 9733053.
27. Passlick B, Pantel K, Kubuschok B, Angstwurm M, Neher A, Thetter O, Schweiberer L, Izbicki JR. Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 1996, 32A:141-145.